All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

A Phase 3, Open-label Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Experienced Disease Progression Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (HARMONi-10)

This clinical trial is looking at a new treatment option for adults with stage 3 non-small cell lung cancer. Specifically, it involves patients whose cancer cannot be removed with surgery and has not grown or spread after completing combined chemotherapy and radiotherapy. The study compares a new drug called ivonescimab with an existing standard medicine called durvalumab (also known as Imfinzi). Both medicines are given through a drip into a vein. Researchers want to see if ivonescimab helps people live longer without their cancer growing back compared to the standard treatment. Taking part involves having regular clinic visits for treatment, blood tests, and scans to monitor health and check how the cancer is responding. Half the people in the trial will receive ivonescimab, while the other half will receive durvalumab.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Summit Therapeutics Inc.
Enrolment target
183
Start
06 Nov 2026

What is this study about?

Lung cancer is one of the most common cancers in the UK. Non-small cell lung cancer is the most frequent type. In stage 3, the cancer has spread into nearby lymph nodes or tissues in the chest, which often means surgeons cannot safely remove it. The usual first step in treatment is chemoradiotherapy, which combines chemotherapy drugs with radiotherapy given at the same time.

After chemoradiotherapy finishes, doctors often give an extra medicine called 'consolidation therapy' to help keep the cancer from coming back or growing. Currently, a medicine called durvalumab is commonly used for this in the NHS. Durvalumab works by helping the body's immune system fight off remaining cancer cells.

This study, called HARMONi-10, is testing a new drug called ivonescimab. Ivonescimab is designed to fight cancer in two ways at once: by boosting the immune system and by blocking the blood supply that tumours need to grow. Doctors want to find out whether ivonescimab works better than durvalumab at keeping the cancer under control, helping patients live longer, and protecting their day-to-day quality of life.

Key takeaways

  • The trial compares a new drug, ivonescimab, against the current standard treatment, durvalumab.
  • It is for adults with stage 3 non-small cell lung cancer that cannot be removed by surgery.
  • Participants must have recently completed chemotherapy and radiotherapy with stable or shrinking cancer.
  • Both treatments are given as an infusion into a vein at regular hospital visits.
  • Participation is entirely voluntary, and you can withdraw at any point.

Who may be eligible?

This trial is for adults aged 18 and older who have been diagnosed with stage 3 non-small cell lung cancer that cannot be removed through an operation. Both men and women can take part.

To be suitable, participants must have recently finished standard chemoradiotherapy (a mix of platinum-based chemotherapy and radiotherapy given together). Importantly, scans must show that the cancer has stayed stable or shrunk after this treatment, rather than grown.

People might not be able to take part if their cancer has worsened, if it has spread to distant parts of the body, or if they have other serious health problems that make the trial treatments unsafe. Your hospital doctor or the study team will carry out detailed checks to confirm if you meet all safety criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with stage 3 non-small cell lung cancer.
  3. My cancer cannot be removed with surgery.
  4. I have recently finished combined platinum-based chemotherapy and radiotherapy.
  5. My most recent scans show that my cancer has not worsened or spread since completing chemoradiotherapy.
Answer every question to see your result.

What does participation involve?

If you take part in this study, you will be assigned to receive either ivonescimab or the standard medicine, durvalumab. Because this is an open-label study, you and your doctor will know which drug you are getting. Both medicines are given as a liquid drip into a vein (an intravenous infusion) at the hospital.

You will need to attend regular hospital appointments to receive your medicine. During these visits, the study team will check your overall health, ask about any symptoms or side effects, and take routine blood and urine samples. You will also have periodic CT or MRI scans so doctors can monitor your cancer closely.

You will continue to receive the study treatment for as long as it helps keep your cancer under control and you do not experience troublesome side effects. After finishing treatment, the medical team will keep in touch with you for regular follow-up checks to see how you are doing over the long term.

Potential risks and benefits

Taking part may give you access to a new treatment that could help keep your cancer from growing for longer, though this cannot be guaranteed. You will also receive very close medical care and frequent monitoring from cancer specialists. However, both ivonescimab and durvalumab can cause side effects. Because these drugs affect the immune system, they can sometimes cause inflammation in organs such as the lungs, bowels, or liver, as well as fatigue, skin rashes, or infusion reactions. Taking part requires frequent visits to the hospital for drips and scans, which can be time-consuming. You are free to leave the trial at any time without giving a reason, and your regular NHS medical care will continue as normal.

Locations (8)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Ireland
  • —
    Unverified
    Greece
  • —
    Unverified
    Italy
  • —
    Unverified
    Spain
  • —
    Unverified
    Romania
  • —
    Unverified
    Germany
  • —
    Unverified
    France
  • —
    Unverified
    Poland

Common questions

What is the main purpose of this study?

The study aims to see if the new medicine, ivonescimab, is more effective than the current standard drug, durvalumab, at stopping stage 3 lung cancer from returning after chemoradiotherapy.

Can I choose which medicine I receive?

No. A computer system assigns participants by chance to receive either ivonescimab or durvalumab, ensuring the comparison is fair and scientifically valid.

Will I know which treatment I am getting?

Yes. This is an 'open-label' study, which means both you and your medical team will know whether you are receiving ivonescimab or durvalumab.

How often will I need to visit the hospital?

You will need to visit the hospital regularly to receive your infusions, usually every few weeks, as well as for routine scans, blood tests, and doctor check-ups.

What happens if my cancer gets worse during the study?

If scans show that your cancer has grown or if you experience unacceptable side effects, the study medicine will be stopped, and your doctor will discuss alternative treatment options with you.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.